Granted Patent
B2
US 12,396,963 · App. 17/777,734 · Granted Aug 26, 2025
Cannabidiol-type cannabinoid compound
Inventors:
Geoffrey Guy (Cambridge, GB); Volker Knappertz (Cambridge, GB); Benjamin Whalley (Cambridge, GB); Marie Woolley-Roberts (Cambridge, GB)
Assignee:
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C1 (CBD-C1), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the 5 cannabinoid can be produced by synthetic means and a method for the production of CBD-C1 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C1 in models of disease.
Claims (7)
1. A method of treating epilepsy in a subject in need thereof, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of cannabidiol-C1 (CBD-C1) as the only active ingredient.
2. The method of claim 1 , wherein the CBD-C1 is in the form of a plant extract.
3. The method of claim 1 , wherein the CBD-C1 is in the form of a synthetic compound.
4. The method of claim 1 , wherein the dose of CBD-C1 is from 100 mg/kg/day to 1 mg/kg/day.
5. The method of claim 1 , wherein the epilepsy treated is in a mammal.
6. The method of claim 5 , wherein the mammal is a human.
7. The method of claim 5 , wherein the mammal is a dog.
Assignments (3)
CHANGE OF NAME
Recorded May 19, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071152/0936 →
SECURITY AGREEMENT
Recorded Jul 26, 2024
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 23, 2023
From: GUY, GEOFFREY; KNAPPERTZ, VOLKER; WHALLEY, BENJAMIN; WOOLLEY-ROBERTS, MARIE
To: GW RESEARCH LIMITED
Reel/Frame 062448/0368 →
Priority Claims (1)
GB 1916846
· Nov 19, 2019
· national
Continuity (1)
References Cited (248)
US 8632825B2
· Velasco Diez et al.
· 2014
[cited by applicant]
US 8790719B2
· Parolaro et al.
· 2014
[cited by applicant]
US 9017737B2
· Kikuchi et al.
· 2015
[cited by applicant]
US 9125859B2
· Whalley et al.
· 2015
[cited by applicant]
US 9474726B2
· Guy et al.
· 2016
[cited by applicant]
US 9949936B2
· Guy et al.
· 2018
[cited by applicant]
US 9949937B2
· Guy et al.
· 2018
[cited by applicant]
US 9956183B2
· Guy et al.
· 2018
[cited by applicant]
US 9956184B2
· Guy et al.
· 2018
[cited by applicant]
US 9956185B2
· Guy et al.
· 2018
[cited by applicant]
US 9956186B2
· Guy et al.
· 2018
[cited by applicant]
US 20140298511A1
· Lewis et al.
· 2014
[cited by applicant]
US 20150359756A1
· Guy et al.
· 2015
[cited by applicant]
US 20170239193A1
· Guy et al.
· 2017
[cited by applicant]
US 20180071210A1
· Wilkhu et al.
· 2018
[cited by applicant]
US 20180228751A1
· Stott et al.
· 2018
[cited by applicant]
US 20190167583A1
· Shah
· 2019
[cited by applicant]
US 20190314296A1
· Wright et al.
· 2019
[cited by applicant]
US 20190321307A1
· Guy et al.
· 2019
[cited by applicant]
US 20190365667A1
· Wright et al.
· 2019
[cited by applicant]
US 20200138738A1
· Guy et al.
· 2020
[cited by applicant]
US 20200179303A1
· Guy et al.
· 2020
[cited by applicant]
US 20200206153A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200237683A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200297656A1
· Guy et al.
· 2020
[cited by applicant]
US 20200352878A1
· Guy et al.
· 2020
[cited by applicant]
US 20210015789A1
· Guy et al.
· 2021
[cited by applicant]
US 20210052512A1
· Guy et al.
· 2021
[cited by applicant]
US 20210059949A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059960A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059976A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210169824A1
· Guy et al.
· 2021
[cited by applicant]
US 20210290565A1
· Guy et al.
· 2021
[cited by applicant]
US 20210330636A1
· Guy et al.
· 2021
[cited by applicant]
US 20210346277A1
· Boyer
· 2021
[cited by examiner]
US 20210401771A1
· Guy et al.
· 2021
[cited by applicant]
US 20220000800A1
· Guy et al.
· 2022
[cited by applicant]
US 20220008355A1
· Guy et al.
· 2022
[cited by applicant]
US 20220016048A1
· Guy et al.
· 2022
[cited by applicant]
US 20220023232A1
· Guy et al.
· 2022
[cited by applicant]
US 20220040155A1
· Guy et al.
· 2022
[cited by applicant]
US 20220062197A1
· Stott et al.
· 2022
[cited by applicant]
US 20220062211A1
· Stott et al.
· 2022
[cited by applicant]
US 20220087951A1
· Knappertz
· 2022
[cited by applicant]
US 20220168266A1
· Guy et al.
· 2022
[cited by applicant]
US 20220183997A1
· Guy et al.
· 2022
[cited by applicant]
US 20220184000A1
· Guy et al.
· 2022
[cited by applicant]
US 20220202738A1
· Guy et al.
· 2022
[cited by applicant]
US 20220211629A1
· Wilkhu et al.
· 2022
[cited by applicant]
US 20220226257A1
· Guy et al.
· 2022
[cited by applicant]
US 20220233495A1
· Silcock et al.
· 2022
[cited by applicant]
US 20220249396A1
· Guy et al.
· 2022
[cited by applicant]
US 20220257529A1
· Guy et al.
· 2022
[cited by applicant]
US 20220265573A1
· Guy et al.
· 2022
[cited by applicant]
US 20220395471A1
· Guy et al.
· 2022
[cited by applicant]
US 20230032502A1
· Guy et al.
· 2023
[cited by applicant]
US 20230038423A1
· Silcock et al.
· 2023
[cited by applicant]
US 20230143812A1
· Knappertz et al.
· 2023
[cited by applicant]
US 20230235825A1
· Thompson et al.
· 2023
[cited by applicant]
US 20230277560A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277561A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277562A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277563A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285419A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285420A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285421A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285422A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285423A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285424A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285426A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285428A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230301936A1
· Guy et al.
· 2023
[cited by applicant]
US 20230310464A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230346809A1
· Craig
· 2023
[cited by applicant]
US 20230372367A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230372368A1
· Checketts et al.
· 2023
[cited by applicant]
US 20240016819A1
· Craig
· 2024
[cited by applicant]
US 20240025858A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240033229A1
· Guy et al.
· 2024
[cited by applicant]
US 20240033272A1
· Checketts et al.
· 2024
[cited by applicant]
US 20240050452A1
· Craig et al.
· 2024
[cited by applicant]
US 20240091241A1
· Guy et al.
· 2024
[cited by applicant]
US 20240130981A1
· Wilkhu
· 2024
[cited by applicant]
US 20240131041A1
· Tse
· 2024
[cited by applicant]
US 20240165048A1
· Guy
· 2024
[cited by applicant]
US 20240207220A1
· Guy et al.
· 2024
[cited by applicant]
US 20240215910A1
· Tse et al.
· 2024
[cited by applicant]
US 20240226032A9
· Wilkhu et al.
· 2024
[cited by applicant]
US 20240226123A9
· Tse
· 2024
[cited by applicant]
US 20240238218A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254066A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254072A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240261234A1
· Guy
· 2024
[cited by applicant]
WO WO0103690A1
· 2001
[cited by applicant]
WO WO2015193667A1
· 2015
[cited by applicant]
WO WO2015193668A1
· 2015
[cited by applicant]
WO WO2016094810A2
· 2016
[cited by applicant]
WO WO2016203239A1
· 2016
[cited by applicant]
WO WO2018061007A1
· 2018
[cited by applicant]
WO WO2018205022A1
· 2018
[cited by applicant]
WO WO2019207319A1
· 2019
[cited by applicant]
WO WO2019219773A1
· 2019
[cited by applicant]
U.S. Appl. No. 15/640,033, filed Jun. 30, 2017.
[cited by applicant]
U.S. Appl. No. 16/467,639, filed Jun. 7, 2019.
[cited by applicant]
U.S. Appl. No. 16/768,241, filed May 29, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,350, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,354, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,357, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 17/050,956, filed Oct. 27, 2020.
[cited by applicant]
U.S. Appl. No. 16/935,005, filed Jul. 21, 2020.
[cited by applicant]
U.S. Appl. No. 17/296,066, filed May 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/296,076, filed May 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/424,682, filed Jul. 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/426,442, filed Jul. 28, 2021.
[cited by applicant]
U.S. Appl. No. 17/406,401, filed Aug. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/435,892, filed Sep. 2, 2021.
[cited by applicant]
U.S. Appl. No. 17/470,382, filed Sep. 9, 2021.
[cited by applicant]
U.S. Appl. No. 17/472,000, filed Sep. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/472,016, filed Sep. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/548,232, filed Dec. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/606,370, filed Oct. 25, 2021.
[cited by applicant]
U.S. Appl. No. 17/611,824, filed Nov. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/529,005, filed Nov. 17, 2021.
[cited by applicant]
U.S. Appl. No. 17/615,422, filed Nov. 30, 2021.
[cited by applicant]
U.S. Appl. No. 17/552,487, filed Dec. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/627,946, filed Jan. 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/631,069, filed Jan. 28, 2022.
[cited by applicant]
U.S. Appl. No. 17/638,629, filed Feb. 25, 2022.
[cited by applicant]
U.S. Appl. No. 17/689,607, filed Mar. 8, 2022.
[cited by applicant]
U.S. Appl. No. 17/689,245, filed Mar. 8, 2022.
[cited by applicant]
U.S. Appl. No. 17/744,224, filed May 13, 2022.
[cited by applicant]
U.S. Appl. No. 17/705,443, filed Mar. 28, 2022.
[cited by applicant]
U.S. Appl. No. 17/680,048, filed Apr. 11, 2022.
[cited by applicant]
U.S. Appl. No. 17/770,435, filed Apr. 20, 2022.
[cited by applicant]
U.S. Appl. No. 17/770,436, filed Apr. 20, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,184, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,190, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,195, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,183, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,677, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,681, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/841,167, filed Jun. 15, 2022.
[cited by applicant]
U.S. Appl. No. 17/786,949, filed Jun. 17, 2022.
[cited by applicant]
U.S. Appl. No. 17/853,367, filed Jun. 29, 2022.
[cited by applicant]
U.S. Appl. No. 17/816,349, filed Jul. 29, 2022.
[cited by applicant]
U.S. Appl. No. 17/817,753, filed Aug. 5, 2022.
[cited by applicant]
U.S. Appl. No. 18/002,437, filed Dec. 19, 2022.
[cited by applicant]
U.S. Appl. No. 18/005,838, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,841, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,845, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,843, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,847, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,848, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,851, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,852, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,853, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,868, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,959, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,960, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,961, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,125, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,127, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,129, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,131, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,133, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,121, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/161,603, filed Jan. 30, 2023.
[cited by applicant]
U.S. Appl. No. 18/170,235, filed Feb. 16, 2023.
[cited by applicant]
U.S. Appl. No. 18/043,810, filed Mar. 2, 2023.
[cited by applicant]
U.S. Appl. No. 18/044,941, filed Mar. 10, 2023.
[cited by applicant]
U.S. Appl. No. 18/245,856, filed Mar. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/186,792, filed Mar. 20, 2023.
[cited by applicant]
U.S. Appl. No. 18/311,221, filed May 2, 2023.
[cited by applicant]
Baek, S. -H et al., Boron Trifluoride Etherate on Alimina—A Modified Lewis Acid Reagent. An Improved Synthesis of Cannabidiol, Tetrahedron Letters, 26(8):1083-1086 (1985).
[cited by applicant]
EPIDIOLEX® (cannabidiol) oral solution, CV, Prescribing Information, 2018, 30 pages; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
[cited by applicant]
Kimball, A. W. et al., Chemical Protection against Ionizing Radiation, Radiation Research, 7:1-12 (1957).
[cited by applicant]
Lewis, M. M. et al., Chemical Profiling of Medical Cannabis Extracts, ACS Omega, 2:6091-6103 (2017).
[cited by applicant]
Litchfield, J. T. & Wilcoxon, F., A simplified method of evaluating dose-effect experiments, J Pharmacol Exp Ther, 96(2):99-113 (1949).
[cited by applicant]
Loscher, W. et al., The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models, Epilepsy Res., 8:79-94 (1991).
[cited by applicant]
Pertwee, R. G., “The Pharmacology and Therapeutic Potential of Cannabidiol,” Cannabinoids, Chapter 3, DiMarzo, V. (Ed.), pp. 32-83 (2004).
[cited by applicant]
Rosenberg, E. C. et al., Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection, Epilepsy & Behavior, 70:319-327 (2017).
[cited by applicant]
Bow, E. W. & Rimoldi, J. M., “The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation,” Perspectives in Medicinal Chemistry, 8:17-39 (2016); doi: 10.4137/PMC.S32171.
[cited by applicant]
Prandi, C. et al., “Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases,” Molecules, 23:1526 (2018); doi: 10.3390/molecules23071526, 17 pages.
[cited by applicant]
Harvey, D. J., “Characterization of the Butyl Homologues of Delta1-tetrahydrocannabinol, Cannabinol and Cannabidiol in Samples of Cannabis by Combined Gas Chromatography and Mass Spectrometry,” J. Pharm. Pharmac., 28:28…
[cited by applicant]
Hill, T. D. M. et al., “Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB 1 receptor-independent mechanism,” British Journal of Pharmacology, 170(3):679-692 (2013).
[cited by applicant]
Morales, P. et al., “An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol,” Frontiers in Pharmacology, 8:422 (2017); doi:10.3389/fphar.2017.00422, 18 pages.
[cited by applicant]
Vree et al., “Identification of hashish of tetrahydrocannabinol, cannabidiol and cannabinol analogues with a methyl side-chain,” J. Pharm. Pharmac. 24:7-12 (1972).
[cited by applicant]
Cited By (1)